Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: Yahoo! Finance
developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Recent Corporate Highlights Closed on approximately $158.7 million underwritten public offering of 3,450,000 shares of common stock at a public offering price of $46.00 per share, which includes the exercise in full by the underwriters of their overallotment option to purchase additional shares. Granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for Diazoxide Choline Extended-Release (DCCR) for the treatment of adults and children ages four years and older with genetically confirmed Prader-Willi syndrome (PWS) who have hyperphagia. Planned submission of a New Drug Application (NDA) for DCCR in PWS remains on track for mid-2024. Published peer-reviewed paper featuring the comparison of results from the Company's Phase 3 placebo-controlled study
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Soleno Therapeutics Stands with the Prader-Willi Syndrome Community [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics Stands with the Prader-Willi Syndrome CommunityGlobeNewswire
- Soleno Therapeutics, Inc. (NASDAQ: SLNO) was upgraded by analysts at Baird R W to a "strong-buy" rating.MarketBeat
- Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $65.00 to $59.00. They now have an "outperform" rating on the stock.MarketBeat
- INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder Investigation of Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Contact the FirmAccesswire
SLNO
Earnings
- 5/9/24 - Miss
SLNO
Sec Filings
- 5/10/24 - Form 8-K
- 5/9/24 - Form 10-Q
- 5/7/24 - Form 8-K
- SLNO's page on the SEC website